Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Interest & Investment Income (2022 - 2026)

Indivior Pharmaceuticals has reported Interest & Investment Income over the past 5 years, most recently at $3.0 million for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 25.0% year-over-year to $3.0 million; the TTM value through Mar 2026 reached $21.0 million, up 5.0%, while the annual FY2025 figure was $22.0 million, 4.35% down from the prior year.
  • Interest & Investment Income for Q1 2026 was $3.0 million at Indivior Pharmaceuticals, down from $6.0 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $12.0 million in Q3 2023 and troughed at $2.0 million in Q2 2022.
  • A 5-year average of $6.9 million and a median of $6.0 million in 2022 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: soared 450.0% in 2023 and later crashed 58.33% in 2024.
  • Year by year, Interest & Investment Income stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then plummeted by 50.0% to $5.0 million in 2024, then rose by 20.0% to $6.0 million in 2025, then plummeted by 50.0% to $3.0 million in 2026.
  • Business Quant data shows Interest & Investment Income for INDV at $3.0 million in Q1 2026, $6.0 million in Q4 2025, and $6.0 million in Q3 2025.